MTRC is joining ISPOR Europe 2026 in Vienna on 8–11 November — a great venue to discuss the evolving evidence requirements and reimbursement challenges shaping market access for medical technologies in Europe. Visit us at booth #416 to meet our team, or book a meeting in advance with MTRC Director Oleg Borisenko to discuss your specific European market access and evidence strategy needs.

On September 11, 2026, the French National Authority for Health (HAS) published its favorable opinion on the coverage of the SAPIEN M3 transcatheter mitral valve replacement system under the Forfait innovation program.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Smela et al. analyzed recommendations for systematic literature reviews within the EU Joint Clinical Assessment framework and compared them with established evidence-based medicine standards.

In August 2026, the Finnish Coordinating Center for Health Technology Assessment announced the completion of five rapid hospital HTAs in diagnostic imaging, gastrointestinal, neurovascular, peripheral vascular, and some other fields.

On September 3, 2026, the National Association of Statutory Health Insurance Physicians (KBV) announced an increase in funding for human genetic diagnostic services reimbursed through the EBM catalog. The decision was adopted by the Evaluation Committee following the completion of its annual review of the volume of development in human genetic services.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, de Waure et al. presented the conceptual foundation of the European Digital Health Technology Assessment (EDiHTA) framework, developed to support the assessment of digital health technologies across EU member states.

In August 2026, the National Institute for Health and Care Research (NIHR) in England published five Med Tech-related assessments in its HTA Journal, concerning craniectomy in acute subdural hematoma, blood-test monitoring strategies for patients on immunosuppressants, home-testing devices for diagnosing obstructive sleep apnea, an electronic frailty index, and chronic wound dressing.

On August 28, 2026, the Italian Official Gazette published a decree setting the criteria and methods for allocating €10 million annually from 2025 to transplantation activities. Of the total, €7 million per year is earmarked for medical devices used for organ perfusion and for the preservation, transport, and management of organs and tissues, while €3 million supports measures to reduce transplant waiting lists.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of September 14th, we plan to work on 15 projects. Review the complete list of planned activities in this post.

On September 1, 2026, the Institute for Hospital Remuneration Systems (INeK) announced the start of the application process under §6(2) KHEntgG (New Examination and Treatment Methods, NUB) for 2027. The application deadline is October 31, 2026.

In August 2026, the National Institute for Health and Care Excellence (NICE) published a new routine-use HealthTech Guidance (HTG) on ex-situ machine perfusion devices to preserve deceased donor livers for transplantation.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, Campione et al. reviewed methods applied in economic evaluations of digital health technologies published between 2020 and 2024.